Aegerion Pharmaceuticals, Inc.
(NASDAQ : AEGR)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 1.83%54.010.9%$2606.95m
JNJJohnson & Johnson 1.22%159.010.7%$1293.99m
MRKMerck & Co., Inc. -1.04%73.120.7%$1148.48m
BMYBristol-Myers Squibb Co. 2.02%56.531.0%$760.26m
LLYEli Lilly & Co. -1.03%245.331.1%$728.22m
ABBVAbbVie, Inc. 0.95%117.981.9%$587.52m
AZNAstraZeneca Plc -1.06%54.211.0%$290.18m
NVSNovartis AG 0.00%79.950.2%$176.56m
GSKGlaxoSmithKline Plc -0.39%41.310.2%$165.40m
DRNADicerna Pharmaceuticals, Inc. -0.12%38.080.3%$144.50m
VTRSViatris, Inc. -0.12%12.190.0%$141.26m
RPRXRoyalty Pharma Plc -2.66%37.850.1%$111.79m
RGENRepligen Corp. -3.05%260.616.7%$107.09m
BFRIBiofrontera, Inc. -20.57%4.170.0%$104.02m
PTPIPetros Pharmaceuticals, Inc. 4.25%2.700.0%$93.99m

Company Profile

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics/pharmaceuticals to treat cardiovascular and metabolic diseases. It develops lomitapide/AEGR-733, a microsomal triglyceride transfer protein inhibitor small molecule drug for decreasing serum lipids, including cholesterol and triglycerides, as well as to treat atherosclerosis, dyslipidemia, obesity, and pancreatitis. The company also focuses on products for the evaluation and treatment of hyperlipidemia. Aegerion Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Bridgewater, New Jersey.